Between 1995 and 2014, a majority of new drugs and medicines approved by the US Food and Drug Administration (FDA) recouped the average cost of drug development through net discounted sales within a ...

Proponents of price controls are wagering that savings on medicines will outweigh the lost benefits. The opposite is true.

FDA commissioner Scott Gottlieb on Monday explained to attendees of RAPS’ Regulatory Convergence conference some steps FDA is taking to make the clinical end of drug development more efficient and ...

This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues (“The Price of Innovation”), using their published cost estimates along with information on success rates and ...

Competition to create new brand-name drugs is a key driver of innovation in the United States. Unfortunately, it also drives the relentless growth of healthcare spending. That’s because development of ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...

President Donald Trump's latest push to slash prescription drug prices promises relief at the pharmacy counter, but behind the headline savings lie trade-offs that could reshape how drugs are ...

HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, MD, and CMS Administrator Mehmet Oz, MD, announced new FDA guidance aimed at making biosimilar drug development faster and less ...

The Food and Drug Administration is relaxing regulations on biosimilar drugs used for cancer and rare diseases in the hopes of boosting competition and lowering prices for high-cost pharmaceuticals.

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Medicare costs could decrease under a new proposal from the Trump ...

The partnership will combine OpenBench’s discovery platform with Concept Life Sciences’ expertise in medicinal chemistry.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...